Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan targets 'faster than US FDA' medtech approvals, but reimbursement remains a problem

This article was originally published in SRA

Executive Summary

Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent ground breaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, senior vice-president of global strategy and analysis at US medtech industry association AdvaMed.

You may also be interested in...

UK Medicines And Medical Devices Bill Laid Before Parliament

UK health minister Baroness Blackwood will introduce the new UK Medicines and Medical Devices Bill before Parliament today, just before the House of Commons goes into recess. The government wants new legislation for devices and medicines in place before the end of the Brexit transition period.

Analyzing An EU Medtech Regulation Crisis In The Making

EU medical device consultant Trevor Lewis takes note of the recent, if belated, progress towards the building of the post-MDR playing field for medical device companies in Europe, but calls political decision-makers and economic operators to account: getting it right is nothing short of a matter of life and death, he tells In Vivo.

Differentiating In Logistics For Regenerative Medicine’s Exploding Universe

Cryoport is a unique company in its niche – supporting regenerative medicine clinical trials and commercial products with cold chain logistics – and has designs on becoming a full supply chain partner for the biopharma industry. CEO Jerry Shelton explained the company’s current role and future plans to In Vivo during the recent Jefferies Healthcare conference.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts